Free. Unsubscribe any time.
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. filed 73 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 8 reporting owners, covering 129 transactions and 931,679 shares. None carries the SEC's AFF10B5ONE flag; all 73 name a plan in a footnote. 8 results prints are on file in the same window.
What stands out
- The most recent filing on file, dated 2026-08-19, came on the same day as the one before it (2026-08-19) and reports 2 transactions against 4 in the filing before it.
- The sales it reports total 6,018 shares, 1,018 more than the 5,000 in the filing before it.
- Its 73 plan statements rank 56th of the 483 companies the register carries in Delaware, its state of incorporation.
- Of the 10 companies the register lists beside it in its industry, 2 have more plan statements on file than it and 8 have fewer.
- Its 73 filings on file run from 2025-01-07 to 2026-08-19, and state 7 plan adoption dates, from 2023-06-26 to 2026-03-18.
Trades in Enliven Therapeutics, Inc. 129
- Hohl Benjamin — 2025-01-03 · S · 1,000 shares
- Patel Anish — 2025-01-07 · S · 20,260 shares
- Patel Anish — 2025-01-07 · S · 1,440 shares
- Patel Anish — 2025-01-07 · S · 6,577 shares
- Patel Anish — 2025-01-07 · S · 90 shares
- Hohl Benjamin — 2025-01-27 · S · 3,250 shares
- Hohl Benjamin — 2025-02-05 · S · 1,000 shares
- Patel Anish — 2025-02-07 · S · 6,667 shares
- Hohl Benjamin — 2025-02-27 · S · 3,250 shares
- Patel Anish — 2025-03-07 · S · 6,667 shares
- Kintz Samuel — 2025-03-17 · S · 12,500 shares
- Lyssikatos Joseph P — 2025-03-19 · S · 12,500 shares
Adoption dates in Enliven Therapeutics, Inc. 7
- 2023-06-26 — stated in 14 filings
- 2024-09-30 — stated in 13 filings
- 2024-11-15 — stated in 31 filings
- 2025-04-08 — stated in 1 filing
- 2025-10-19 — stated in 9 filings
- 2026-03-06 — stated in 2 filings
- 2026-03-18 — stated in 3 filings
Results prints in Enliven Therapeutics, Inc. 8
- 2025-03-13
- 2025-05-14
- 2025-08-13
- 2025-11-12
- 2025-11-13
- 2026-03-03
- 2026-05-07
- 2026-08-05
Trades before a print in Enliven Therapeutics, Inc. 3
- 1 day before the 2026-08-05 print — 2026-08-04 · S · Derynck Mika K · 158,795 shares
- 5 days before the 2025-11-12 print — 2025-11-07 · S · Patel Anish · 6,054 shares
- 5 days before the 2025-11-12 print — 2025-11-07 · S · Patel Anish · 613 shares
- 6 days before the 2025-03-13 print — 2025-03-07 · S · Patel Anish · 6,667 shares
- 6 days before the 2025-08-13 print — 2025-08-07 · S · Patel Anish · 6,262 shares
- 6 days before the 2025-08-13 print — 2025-08-07 · S · Patel Anish · 405 shares
- 7 days before the 2025-05-14 print — 2025-05-07 · S · Patel Anish · 6,173 shares
- 7 days before the 2025-05-14 print — 2025-05-07 · S · Patel Anish · 390 shares
- 7 days before the 2025-05-14 print — 2025-05-07 · S · Patel Anish · 104 shares
- 12 days before the 2025-05-14 print — 2025-05-02 · S · Kintz Samuel · 2,170 shares
- 12 days before the 2025-05-14 print — 2025-05-02 · S · Lyssikatos Joseph P · 2,470 shares
- 13 days before the 2025-05-14 print — 2025-05-01 · S · Kintz Samuel · 5,330 shares
Interval to Enliven Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 3within 5 days
- 9within 10 days
- 1shortest, days
- 4no later print
- Patel Anish 2025-03-07 · S · 6 days before the 2025-03-13 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-05-07 · S · 7 days before the 2025-05-14 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-05-07 · S · 7 days before the 2025-05-14 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-05-07 · S · 7 days before the 2025-05-14 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-08-07 · S · 6 days before the 2025-08-13 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-08-07 · S · 6 days before the 2025-08-13 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-11-07 · S · 5 days before the 2025-11-12 print · CHIEF OPERATING OFFICER
- Patel Anish 2025-11-07 · S · 5 days before the 2025-11-12 print · CHIEF OPERATING OFFICER
- Derynck Mika K 2026-08-04 · S · 1 day before the 2026-08-05 print
Adoption dates Enliven Therapeutics, Inc. states
- 2023-06-26 in 14 filings
- 2024-09-30 in 13 filings
- 2024-11-15 in 31 filings
- 2025-04-08 in 1 filing
- 2025-10-19 in 9 filings
- 2026-03-06 in 2 filings
- 2026-03-18 in 3 filings
Filing text: “10b5-1 trading plan adopted by the Reporting Person on June 26, 2023”
Reported results dates on file
- 2025-03-13
- 2025-05-14
- 2025-08-13
- 2025-11-12
- 2025-11-13
- 2026-03-03
- 2026-05-07
- 2026-08-05
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 2
- FMC CORP 2
- ELI LILLY & Co 11
- ABEONA THERAPEUTICS INC. 7
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 37
- Lifevantage Corp 3
- IONIS PHARMACEUTICALS INC 86
- VERTEX PHARMACEUTICALS INC / MA 74
- ARROWHEAD PHARMACEUTICALS, INC. 23
Sources: SEC EDGAR full-text search and the SEC submissions API.